The ‘sell down’ has been going on since Highs of 14 cents plus last year. Furthermore, 3ys also confirm that at least one major has weakened their hold status since two years ago CR which was at 9 cents and doubled the registry or doubled the dilution. Manipulation? Vague term, held down..., yes. Why? We will see. Sure, a couple of set back with anticipated results I.e., both ovarian and AML trials extended to meet end points didn’t avail to timeline..., yet that spec biotech’s at the experimental stages. Replication on the breastcancer phase 2 should warrant further validation of the ptx-200 compound, hence still (at this ridiculous MC) a strong hold.
PTX Price at posting:
7.0¢ Sentiment: Hold Disclosure: Held
